Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States
Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States
复制标题
DOI：
10.1093/cid/cis361
复制
发表时间：
2012-07-15
影响因子：
11.8
通讯作者：
Holtzman, Deborah
中科院分区：
文献类型：
--
作者：
Averhoff, Francisco M.;Glass, Nancy;Holtzman, Deborah
据估计，世界人口中有 2%-3% 感染丙型肝炎病毒 (HCV)，每年有超过 35 万人死于 HCV 相关疾病，包括肝硬化和肝癌。世界各地 HCV 感染的流行病学和负担各不相同，具体国家的患病率范围从 < 1% 到 > 10%。与美国和其他发达国家相比，发展中国家的丙型肝炎病毒传播通常是由于在医疗保健和社区环境中接触受感染的血液造成的。丙型肝炎的预防、护理和治疗计划必须认识到特定国家的流行病学，该流行病学因环境和经济发展水平而异。了解 HCV 感染的全球流行病学对于美国医疗保健提供者治疗来自 HCV 感染流行国家的外国出生患者以及为前往这些国家旅行的患者提供咨询非常重要。 HCV 感染负担重的国家也将受益于建立全面的预防、护理和治疗计划。
An estimated 2%-3% of the world's population is living with hepatitis C virus (HCV) infection, and each year, > 350 000 die of HCV-related conditions, including cirrhosis and liver cancer. The epidemiology and burden of HCV infection varies throughout the world, with country-specific prevalence ranging from < 1% to > 10%. In contrast to the United States and other developed countries, HCV transmission in developing countries frequently results from exposure to infected blood in healthcare and community settings. Hepatitis C prevention, care, and treatment programs must recognize country-specific epidemiology, which varies by setting and level of economic development. Awareness of the global epidemiology of HCV infection is important for US healthcare providers treating foreign-born patients from countries where HCV infection is endemic and for counseling patients who travel to these countries. Countries with a high burden of HCV infection also would benefit from establishing comprehensive prevention, care, and treatment programs.